DLBCL

A dual-target PI3 kinase inhibitor demonstrated activity in several types of relapsed and refractory non-Hodgkin lymphoma.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Adding the BTK inhibitor ibrutinib to standard rituximab (R)-CHOP chemotherapy for non-Hodgkin lymphoma (NHL) resulted in an objective response rate of 100%.

The FDA has received a new drug application for ibrutinib as a therapy for previously treated CLL and previously treated MCL.

Patients with chronic lymphocytic leukemia (CLL) and patients with mantle cell lymphoma (MCL) showed high response rates to therapy with ibrutinib.

Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.

Lenalidomide has been approved to treat patients with mantle cell lymphoma who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.

A phase III study of inotuzumab ozogamicin for patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for high-dose chemotherapy was halted after a scheduled interim analysis.

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, describes the mechanism of action of antibody drug conjugates and their use.